用于管理动脉粥样硬化性心血管疾病风险的新胆固醇指南：2013年美国心脏病学会/美国心脏协会胆固醇指南与2014年美国国家脂质协会以患者为中心的血脂异常管理建议的比较
New Cholesterol Guidelines for the Management of Atherosclerotic Cardiovascular Disease Risk: A Comparison of the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines with the 2014 National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia.
作者信息
Adhyaru Bhavin B, Jacobson Terry A
机构信息
Division of General Internal Medicine & Geriatrics, Department of Medicine, Emory University School of Medicine, 49 Jesse Hill Jr Drive, Atlanta, GA 30303, USA.
Lipid Clinic and Cardiovascular Risk Reduction Program, Department of Medicine, Emory University School of Medicine, 49 Jesse Hill Jr Drive, Atlanta, GA 30303, USA.
出版信息
Endocrinol Metab Clin North Am. 2016 Mar;45(1):17-37. doi: 10.1016/j.ecl.2015.09.002.
This review discusses the 2013 American College of Cardiology (ACC)/American Heart Association (AHA) Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults and compares it with the 2014 National Lipid Association (NLA) Recommendations for Patient-Centered Management of Dyslipidemia. The review discusses some of the distinctions between the guidelines, including how to determine a patient's atherosclerotic cardiovascular disease risk, the role of lipoprotein treatment targets, the importance of moderate- and high-intensity statin therapy, and the use of nonstatin therapy in light of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) trial.
本综述讨论了2013年美国心脏病学会（ACC）/美国心脏协会（AHA）《降低成人动脉粥样硬化性心血管疾病风险的血脂治疗指南》，并将其与2014年美国国家脂质协会（NLA）《以患者为中心的血脂异常管理建议》进行比较。该综述讨论了这些指南之间的一些差异，包括如何确定患者的动脉粥样硬化性心血管疾病风险、脂蛋白治疗目标的作用、中等强度和高强度他汀类药物治疗的重要性，以及根据改善转归：依折麦布国际试验（IMPROVE-IT）试验使用非他汀类药物治疗的情况。
Zotero 插件